Home » NOSTRUM PHARMACEUTICALS OBTAINS WORLDWIDE LICENSING RIGHTS FROM IMTECH FOR CLINICAL DEVELOPMENT OF A NOVEL CLOT BUSTING THERAPEUTIC PROTEIN
NOSTRUM PHARMACEUTICALS OBTAINS WORLDWIDE LICENSING RIGHTS FROM IMTECH FOR CLINICAL DEVELOPMENT OF A NOVEL CLOT BUSTING THERAPEUTIC PROTEIN
Pharmaceuticals Inc., a privately held company based in Kendall Park, New Jersey, announced that it has obtained a worldwide license from Institute of Microbial Technology (IMTECH), Chandigarh, India, to carry out clinical development and commercialization of a novel clot busting therapeutic protein.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May